NCT02942095 2023-04-18
Study of Ixazomib and Erlotinib in Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
8 trialsNCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01284335 2019-01-10
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00895687 2015-07-13
Study of Erlotinib in Combination With Bortezomib
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00903734 2015-07-13
An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00611468 2011-08-22
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
Accelerated Community Oncology Research Network
Phase 1 Completed